13F reference period
Q2 2026
Security Snapshot
Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (PTHS) Institutional Ownership
CUSIP: 171126204
13F Institutional Holders and Ownership History from Q3 2025 to Q3 2026
Institutions Reporting
23
Shares (Excl. Options)
1.32M
Full value: 1,323,157 · shares · 30 Jun 2026Price
$28.26
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- PTHS on NYSE
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 1,323,157
- Total 13F value
- $37,392,417
- Portfolio coverage rank
- 0%
- Share change
- +410,846
- Value change
- +$11,624,481
- Number of holders
- 23
- Shares outstanding
- 3,332,442
- SEC-reported price per share
- $21.00
- Insider filing price
- $21.00
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- PTHS - Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 171126204.
- 23 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 17 to 23 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$19.17M
Full value: $19,167,664 · USD · 31 Mar 2026.$37.39M
Full value: $37,392,417 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 23 institutions filings for Q2 2026.
Security key
171126204
13F reference period
Q2 2026
13F holders
23
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
PTHS full holder history
Pelthos Therapeutics Inc. SEC filings
Pelthos Therapeutics Inc. company facts
Pelthos Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 171126204:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
PTHS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| LIGAND PHARMACEUTICALS INC | 50% | 0% | $145,296,959 | +$7,316,652 | 5,189,177 | +5.3% | Ligand Pharmaceuticals Incorporated | 06 Nov 2025 |
| 3i, LP | 9.9% | 0% | $7,751,598 | +$417,220 | 337,026 | +5.7% | 3i, LP | 31 Mar 2026 |
| Murchinson Ltd. | 9.1% | $7,840,000 | 280,000 | Murchinson Ltd. | 30 Sep 2025 | |||
| Ikarian Capital, LLC | 7.7% | -8.8% | $5,901,754 | +$19,320 | 256,598 | +0.33% | Ikarian Capital, LLC | 31 Mar 2026 |
| Friedberg Ezra M | 8.3% | 250,121 | Ezra Friedberg | 01 Jul 2025 |
As of 30 Jun 2026,
23
institutional investors reported holding
shares of
Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (PTHS).
This represents
40%
of the company’s total
outstanding shares.
1.32M
Full value: 1,323,157 · shares · 30 Jun 20263.33M
Full value: 3,332,442 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
40%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| AIGH Capital Management LLC | 9.9% | 329,098 | 0.84% | $9,300,309 | |
| Murchinson Ltd. | 9.1% | 304,302 | +2.7% | 4.2% | $8,599,575 |
| Ikarian Capital, LLC | 7.7% | 256,598 | 0% | 1.2% | $7,251,459 |
| BOOTHBAY FUND MANAGEMENT, LLC | 3.1% | 101,976 | +25% | 0.06% | $2,881,842 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.9% | 97,134 | +4.3% | 0% | $2,745,007 |
| CANTOR FITZGERALD, L. P. | 1.1% | 38,123 | -8% | 0.02% | $1,077,356 |
| J. Goldman & Co LP | 1.1% | 38,075 | -24% | 0.04% | $1,076,000 |
| DIADEMA PARTNERS LP | 0.74% | 24,773 | 0% | 0.26% | $700,085 |
| WEXFORD CAPITAL LP | 0.67% | 22,364 | 0.09% | $632,007 | |
| Knott David M Jr | 0.66% | 22,073 | +4.7% | 0.34% | $623,783 |
| CITADEL ADVISORS LLC | 0.45% | 15,046 | 0% | $425,200 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.44% | 14,650 | -4.2% | 0% | $414,008 |
| Pale Fire Capital SE | 0.39% | 12,919 | 0% | 0.03% | $365,091 |
| 1492 Capital Management LLC | 0.31% | 10,380 | 0.09% | $293,339 | |
| VANGUARD FIDUCIARY TRUST CO | 0.3% | 9,873 | +0.57% | 0% | $279,011 |
| STATE STREET CORP | 0.29% | 9,800 | 0% | $276,948 | |
| Persistent Asset Partners Ltd | 0.18% | 6,007 | 0% | 0.05% | $169,758 |
| BlackRock, Inc. | 0.16% | 5,324 | 0% | $150,457 | |
| UBS Group AG | 0.07% | 2,217 | +190% | 0% | $62,652 |
| China Universal Asset Management Co., Ltd. | 0.06% | 2,160 | 0% | $61,042 | |
| Tower Research Capital LLC (TRC) | 0.01% | 205 | 0% | $5,793 | |
| Farther Finance Advisors, LLC | 0% | 40 | 0% | 0% | $1,130 |
| BARCLAYS PLC | 0% | 20 | 0% | $565 | |
| Aspect Partners, LLC | 0% | 0 | -100% | $0 | |
| CITIGROUP INC | 0% | 0 | -100% | $0 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
5
Headline period
Q2 2026
Rows shown
1-5 of 5
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 40 | $840 | $21.00 | 1 | |
| 2026 Q2 | 1,323,157 | $37,392,417 | +$11,624,481 | $28.26 | 23 |
| 2026 Q1 | 912,311 | $19,167,664 | -$424,416 | $21.01 | 17 |
| 2025 Q4 | 899,359 | $27,880,129 | +$13,536,994 | $31.00 | 15 |
| 2025 Q3 | 462,762 | $12,957,336 | +$12,957,336 | $28.00 | 14 |